Skip to content

This is a promotional website fully funded and created by SERB Pharmaceuticals for UK Healthcare Professionals only.

Order Voraxaze

You are viewing the Voraxaze▼(glucarpidase) website for the United Kingdom.

Certain BTG products may not be available within the chosen
location, and indications may differ from your country's approved use.

I am a patient

Continue

I am a Healthcare Professional

Outside of the UK

United States (EN) Germany (DE)

I am a Healthcare Professional
In the UK

UK-VRX-2600029 Date of Last Revision: February 2026

Posology

VORAXAZE® PRESENTATION1

Voraxaze® 1 000 units powder for solution for injection
White to off-white powder for solution for injection
After reconstitution with 1 mL of sterile 0.9% sodium chloride solution, each vial contains a nominal 1000 units of Voraxaze®†

† Produced in Escherichia coli cells by recombinant DNA technology.

Pack-vial-new_2

POSOLOGY1

14

Abbreviations: HDMTX, high dose methotrexate; IV, intravenous; MTX, methotrexate.

†Infusion durations are specific to each protocol and indication (from 2 to 36 hours).2,3

††Clinical data shows Voraxaze® continues to be effective beyond this time window.

ihttps://www.medicines.org.uk/emc/product/9649/smpc/print

References

  1. Summary of Product Characteristics (SmPC), Voraxaze®.
  2. Ramsey LB, et al. Consensus guideline for use of glucarpidase in patients with high-dose methotrexate induced acute kidney injury and delayed methotrexate clearance. Oncologist. 2018;23(1):52-61.
  3. Howard SC, et al. Preventing and managing toxicities of high-dose methotrexate. Oncologist. 2016;21(12):1471-82.

UK-VRX-2600034 Date of Last Revision: February 2026